Parkman Healthcare Partners LLC Sells 107,241 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)

Parkman Healthcare Partners LLC lessened its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 25.4% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 314,541 shares of the company's stock after selling 107,241 shares during the quarter. Parkman Healthcare Partners LLC owned approximately 0.78% of Keros Therapeutics worth $4,979,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of KROS. AlphaQuest LLC increased its stake in shares of Keros Therapeutics by 469.0% in the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company's stock valued at $57,000 after purchasing an additional 2,964 shares in the last quarter. Virtus ETF Advisers LLC increased its stake in shares of Keros Therapeutics by 107.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company's stock worth $61,000 after buying an additional 1,998 shares during the period. KLP Kapitalforvaltning AS acquired a new position in shares of Keros Therapeutics during the fourth quarter worth $90,000. Exchange Traded Concepts LLC acquired a new stake in shares of Keros Therapeutics during the fourth quarter worth about $99,000. Finally, CANADA LIFE ASSURANCE Co grew its stake in shares of Keros Therapeutics by 207.8% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 7,371 shares of the company's stock valued at $116,000 after purchasing an additional 4,976 shares during the last quarter. Institutional investors own 71.56% of the company's stock.

Keros Therapeutics Price Performance

Keros Therapeutics stock opened at $13.47 on Wednesday. The company has a market cap of $547.08 million, a price-to-earnings ratio of -2.59 and a beta of 1.32. Keros Therapeutics, Inc. has a one year low of $9.12 and a one year high of $72.37. The firm has a 50-day moving average of $12.27 and a 200-day moving average of $23.83.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $3.62 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $3.63. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $211.25 million during the quarter, compared to analysts' expectations of $84.62 million. During the same period in the previous year, the firm earned ($1.21) EPS. As a group, sell-side analysts expect that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Insiders Place Their Bets

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of Keros Therapeutics stock in a transaction dated Wednesday, April 9th. The stock was purchased at an average price of $10.13 per share, for a total transaction of $9,464,033.54. Following the completion of the purchase, the insider now directly owns 4,392,737 shares of the company's stock, valued at approximately $44,498,425.81. This trade represents a 27.01% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 22.90% of the company's stock.

Wall Street Analyst Weigh In

KROS has been the subject of a number of research analyst reports. HC Wainwright reduced their price target on shares of Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Oppenheimer cut their price objective on shares of Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating on the stock in a report on Thursday, January 16th. Scotiabank decreased their target price on shares of Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a research note on Monday. Guggenheim reiterated a "neutral" rating on shares of Keros Therapeutics in a research note on Friday, January 17th. Finally, Wells Fargo & Company decreased their target price on Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, February 27th. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $37.00.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.